Merrimack Pharmaceuticals Inc (MACK)
NASDAQ
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
The current MACK market cap is 224.15M. The company's latest EPS is USD -0.0799 and P/E is -189.74.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 139k | 0 | 0 | 0 | 0 |
| Operating Income | -447k | -569k | -531k | -490k | -669k |
| Net Income | -271k | -391k | -279k | -240k | 201.37M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -27.27M | -5.01M | -2.62M | -2.17M | -2.18M |
| Net Income | -17.33M | -3.03M | -2.46M | -1.54M | -1.18M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 19.64M | 19.45M | 19.3M | 19.19M | 244.32M |
| Total Liabilities | 463k | 411k | 493k | 441k | 22.67M |
| Total Equity | 19.17M | 19.04M | 18.81M | 18.75M | 221.65M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 20.08M | 16.78M | 14.75M | 19.84M | 19.19M |
| Total Liabilities | 2.77M | 770k | 562k | 589k | 441k |
| Total Equity | 17.31M | 16.01M | 14.19M | 19.25M | 18.75M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -356k | -1.02M | -1.23M | -1.52M | -1.31M |
| Investing | 139k | -8.67M | -12.52M | -12.45M | 228M |
| Financing | 179k | 388k | 388k | 521k | 1.49M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -31.37M | -4.63M | -218k | -1.74M | -1.52M |
| Investing | 69.83M | 2.14M | 144k | 445k | -12.45M |
| Financing | -42.54M | -56k | 239k | 6.53M | 521k |
| Market Cap | 224.15M |
| Price to Earnings Ratio | -189.74 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 37.43 |
| Price to Book Ratio | 11.96 |
| Dividend Yield | 99.62% |
| Shares Outstanding | 14.79M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 22.83% |
| 52 Week High | 15.89 |
| 52 Week Low | 12.00 |
| Spread (Intraday) | 0.03 (0.2%) |
| Company Name | Merrimack Pharmaceuticals Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.merrimack.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
